Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy.

Watkins RR, Lemonovich TL, File TM Jr.

Core Evid. 2012;7:131-43. doi: 10.2147/CE.S33430. Epub 2012 Dec 11.

3.

Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus.

Maclayton DO, Hall RG 2nd.

Ann Pharmacother. 2007 Feb;41(2):235-44. Epub 2007 Feb 13. Review.

PMID:
17299012
4.

Health economic evaluation of patients treated for nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus: secondary analysis of a multicenter randomized clinical trial of vancomycin and linezolid.

Niederman MS, Chastre J, Solem CT, Wan Y, Gao X, Myers DE, Haider S, Li JZ, Stephens JM.

Clin Ther. 2014 Sep 1;36(9):1233-1243.e1. doi: 10.1016/j.clinthera.2014.06.029. Epub 2014 Jul 25.

PMID:
25066668
5.

European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid.

Chastre J, Blasi F, Masterton RG, Rello J, Torres A, Welte T.

Clin Microbiol Infect. 2014 Apr;20 Suppl 4:19-36. doi: 10.1111/1469-0691.12450. Review.

6.

Linezolid - the first oxazolidinone in the treatment of nosocomial MRSA pneumonia.

Burkhardt O, Pletz MW, Mertgen CP, Welte T.

Recent Pat Antiinfect Drug Discov. 2007 Jun;2(2):123-30. Review.

PMID:
18221168
7.

Methicillin-resistant Staphylococcus aureus nosocomial pneumonia: role of linezolid in the People's Republic of China.

Lesher B, Gao X, Chen Y, Liu Z.

Clinicoecon Outcomes Res. 2016 Mar 24;8:63-72. doi: 10.2147/CEOR.S91985. eCollection 2016. Review.

8.

Treatment of infections due to resistant Staphylococcus aureus.

Anstead GM, Cadena J, Javeri H.

Methods Mol Biol. 2014;1085:259-309. doi: 10.1007/978-1-62703-664-1_16. Review.

PMID:
24085702
9.

Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.

Patel DA, Shorr AF, Chastre J, Niederman M, Simor A, Stephens JM, Charbonneau C, Gao X, Nathwani D.

Crit Care. 2014 Jul 22;18(4):R157. doi: 10.1186/cc13996.

10.

Community-Associated Methicillin-Resistant Staphylococcus aureus in the Pediatric Population.

Nemerovski CW, Klein KC.

J Pediatr Pharmacol Ther. 2008 Oct;13(4):212-25. doi: 10.5863/1551-6776-13.4.212.

11.

Linezolid versus vancomycin for skin and soft tissue infections.

Yue J, Dong BR, Yang M, Chen X, Wu T, Liu GJ.

Cochrane Database Syst Rev. 2016 Jan 7;(1):CD008056. doi: 10.1002/14651858.CD008056.pub3. Review.

PMID:
26758498
12.

[Linezolid in the treatment of antibiotic-resistant gram-positive infections of the musculoskeletal system].

Jahoda D, Nyc O, Pokorný D, Landor I, Sosna A.

Acta Chir Orthop Traumatol Cech. 2006 Oct;73(5):329-33. Czech.

PMID:
17140514
13.

A network meta-analysis of antibiotics for treatment of hospitalised patients with suspected or proven meticillin-resistant Staphylococcus aureus infection.

Bally M, Dendukuri N, Sinclair A, Ahern SP, Poisson M, Brophy J.

Int J Antimicrob Agents. 2012 Dec;40(6):479-95. doi: 10.1016/j.ijantimicag.2012.08.004. Epub 2012 Oct 25. Review.

PMID:
23102749
14.

Linezolid versus vancomycin for skin and soft tissue infections.

Yue J, Dong BR, Yang M, Chen X, Wu T, Liu GJ.

Evid Based Child Health. 2014 Mar;9(1):103-66. doi: 10.1002/ebch.1961.

PMID:
25404579
15.

Linezolid versus vancomycin for skin and soft tissue infections.

Yue J, Dong BR, Yang M, Chen X, Wu T, Liu GJ.

Cochrane Database Syst Rev. 2013 Jul 12;(7):CD008056. doi: 10.1002/14651858.CD008056.pub2. Review. Update in: Cochrane Database Syst Rev. 2016;(1):CD008056.

PMID:
23846850
16.
17.

Role of linezolid in the treatment of complicated skin and soft tissue infections.

Peppard WJ, Weigelt JA.

Expert Rev Anti Infect Ther. 2006 Jun;4(3):357-66. Review.

PMID:
16771613
19.

Supplemental Content

Support Center